Treatment of Submassive Pulmonary Embolism (PE): Full Dose, Half Dose, or No Dose?

Written by Salim Rezaie REBEL EM Medical Category: Thoracic and Respiratory

Submassive pulmonary embolism (PE) is responsible for approximately 20% of all PEs. Although the in-hospital mortality has been reported as about 5%, there is significant morbidity associated with this diagnosis such as chronic pulmonary hypertension, impaired quality of life, persistent right ventricular disfunction, and recurrent venous thromboembolism. The literature suggests that systemic thrombolytics can improve morbidity and maybe mortality, but this comes at the risk of increased major bleeding and intracranial hemorrhage (2 – 3%) when compared to anticoagulation alone.

How is Submassive PE Defined in the Literature:

Acute PE without hypotension (SBP <90mmHg) but with any of the following: RV dysfunction on POCUS RV dilation (RV:LV Diameter >0.9 on POCUS) Elevated BNP (>500pg/mL) Elevated Troponin I (>0.4ng/mL) Elevated Troponin T (>0.1ng/mL) New ECG Changes (Complete or Incomplete RBBB, Anteroseptal ST-Segment Elevation/Depression, or Anterolateral T-Wave Inversion)



What do Different Organizations Say About the Use of Systemic Thrombolytics for Submassive PE:

American College of Chest Physicians (ACCP): NO (Grade IB)

American Heart Association (AHA): Select Patients (Grade IIB)

European Heart Association (EHA): Select Patients

American College of Emergency Physicians (ACEP): Insufficient Evidence to Make a Recommendation

What Does the Twitterverse Say About the Treatment of Submassive PE:

Full Dose Systemic Thrombolytics:

PEITHO Trial (Largest RCT to Date) – 2014 1005 patients with submassive PE and evidence of RV strain Weight based tenecteplase + standard dose parental anticoagulation vs anticoagulation alone Primary Outcome: Death or hemodynamic decompensation Reduced but primarily driven by reduction in hemodynamic decompensation Increased Major Bleeding and ICH (Primarily in patients ≥75 years of age)

(Largest RCT to Date) – 2014 TOPCOAT (Treatment of Submassive PE with Tenecteplace or Placebo: Cardiopulmonary Outcomes at 3 months) – 2014

(Treatment of Submassive PE with Tenecteplace or Placebo: Cardiopulmonary Outcomes at 3 months) – 2014 83 patients with submassive PE

Full Dose Tenecteplase with standard dose heparin vs Placebo with standard dose heparin

Primary Endpoint: Death, Need for intubation or Surgical thrombectomy at 5d and 6 weeks

Improved quality of life, RV function, exercise capacity, and perception of physical wellness at 6 weeks in thrombolytic group but with increased ICH Major Bleeding 0% in both groups ICH Tenecteplase 1/40 (2.5%) Anticoagulation Alone = 0%

MAPPET-3 (Management Strategies and Prognosis of PE Trial-3) – 2002 256 patients double-blinded, randomized clinical trial Alteplase 100mg + standard dose heparin vs placebo + standard dose heparin Primary Endpoint In-Hospital Death or Clinical Deterioration (Need for vasopressors, surgical embolectomy, cardiopulmonary resuscitation, intubation or secondary thrombolysis) No difference in mortality Patients treated with heparin alone had more cases of deterioration No difference in bleeding between groups

(Management Strategies and Prognosis of PE Trial-3) – 2002 Chaterjee S et al 2014 Meta-Analysis All-cause mortality lower with thrombolysis vs anticoagulation alone in patients with moderate and high-risk PE (2.17 vs 3.89%) NNT = 59 Major bleeding and ICH higher in thrombolysis vs anticoagulation alone in patients with moderate and high-risk PE (9.24% vs 3.42%) NNH = 18 and (1.46 vs 0.19%) NNH = 78 Submassive PE mortality lower with thrombolysis vs anticoagulation alone (1.39% vs 2.92%) NNT = 65 Submassive PE major bleeding higher with thrombolysis vs anticoagulation alone (7.74% vs 2.25%) NNH = 18

Clinical Bottom Line: These three studies showed mixed results in terms of mortality benefits. However, there was also a consistent decrease in hemodynamic decompensation and quality of life with full dose thrombolytic therapy. Conversely, there was a uniform increased risk of major bleeding in patients > 65 years of age

Half Dose Systemic Thrombolytics:

MOPETT (Moderate PE Treated with Thrombolysis) Trial Single Center, Unblinded Randomized trial of 121 patients ½ dose tPA + modified dose anticoagulation vs placebo + standard anticoagulation Primary Outcome: Pulm HTN defined by TTE at 28months Thrombolytic Group 16% Anticoagulation Alone 57% NNT = 2 No bleeding in either group No functional outcomes assessed Bottom Line: Improved pulmonary pressures, no functional outcomes assessed, but no increase in major bleeding or ICH

Levine et al – 1990 58 patients Alteplase 0.6mg/kg (Max: 50mg) IV vs Heparine Alone Primary Outcome: Clot Burden on V/Q Scan at 7d and 28d Decreased with thrombolysis vs Anticoagulation alone No Major Bleeding in either group Mortality not assessed Bottom Line: Decreased Clot Burden on V/Q scan with no increase in major bleeding

Clinical Bottom Line: Improves Surrogate outcomes (i.e. Mortality not assessed) but no increased major bleeding

Full Dose vs Half Dose:

Prospective, RCT 118 pts HD Instability or massive pulmonary artery obstruction 24hr & 14days 50mg/2h tPa vs 100mg/2h tPa Any Improvement in Pulmonary Artery Obstruction No difference in primary outcomes at 24hr or 14days Any Bleeding Complications More bleeding complications and major bleeding with full dose thrombolytics

Systematic Review and Meta-Analysis of 5 RCTs (444 patients) – 3 compared full dose vs half dose Low Dose 0.6mg/kg with Max of 50mg vs Full Dose 100mg IV More Major Bleeding Events with Full Dose (OR 0.33) No Statistical Difference in Recurrent PE or Mortality

Clinical Bottom Line: Similar efficacy in death and recurrent PE in patients with massive and submassive PE, but a tendency toward less bleeding with half dose thrombolytics

Full Dose vs Half Dose vs Anticoagulation Alone

Systematic Review and Meta-Analysis of 5 RCTs (444 patients)

Two Studies Compared Low Dose (0.6mg/kg Max 50mg/2hr or 10mg Bolus + ≤40mg/2hr vs heparin drip alone No Difference in Major Bleeding Events, Recurrent PE or All-Cause Mortality Improved Clot Burden 7 days: Levine et al 12% vs 34.4% on V/Q Scan Sharifi et al 16% vs 57% on Echo



Catheter Directed +/- Ultrasound

SEATTLE-2 (2015) Prospective, Single-arm, Multi-center trial of Ekosonic Endovasucular System and Activase for Treatment of Acute Pulmonary Embolism Trial US-Facilitated, catheter directed, low-dose thrombolysis Primary Outcome was RV/LV ratio at 48h Secondary Outcome was Pulmonary Pressure 31 patients with massive PE and 119 with submassive PE Treatment decreased RV dilatation, reduced Pulmonary HTN, decreased clot burden, and minimized risk of ICH in patients with PE, but increased length of hospital stay (8.8d +/- 5) Zero cases of ICH but one groin hematoma that suffered some transient hypotension

PERFECT Trial (2015) Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT) Prospective Multicenter Single-Arm Study 101 Patients Clinical Success = Stabilization of HD, Improvement in Pulm HTN, Improved RV Strain & Survival to Hospital DC Safety Outcomes = Major procedure related Complications & Major Bleeding Events



Clinical BOTTOM LINE:

There is not a clear cut answer based on the available evidence, but with a shared decision making strategy, consideration of patient age (≥65 years vs <65 years) and functional status considerations, some generalizations can be made: Full dose systemic thrombolysis is effective BUT has a high bleeding complication rate. Acceptable /Unacceptable bleeding rates should be discussed on a case by case basis with patients using a shared decision making strategy Low dose systemic thrombolysis has less bleeding with equal efficacy compared to full dose systemic thrombolysis, however more data is needed on mortality outcomes. This may be a good strategy in patients over the age of 65 years who have increased risk of major bleeding and ICH. The evidence for CDT is very scant and not compared to systemic thrombolysis, but it does appear to be more expensive and cause longer length of ICU stay compared to systemic thrombolysis. This may be another option to consider in patients with increased risk of bleeding (i.e. Patients 65 years and older) while balancing cost and use of resources CDT and low dose systemic thrombolysis improve symptoms, hemodynamics, RV/LV size, other echo parameters and PA pressures, but long-term clinical correlates are still lacking



For More on This Topic Checkout:

References:

Sharifi M et al. Systemic Full Dose, Half Dose, And Catheter Directed Thrombolysis for Pulmonary Embolism. When to Use and How to Choose? Curr Treat Options Cardio Med 2016; 18: 31. PMID: 26923384 Long B and Koyfman A. Current Controversies in Thrombolytic Use in Acute Pulmonary Embolism 2016. JEM 51(1): 37 – 44. PMID: 27071316 Kuo WT, Banerjee A, Kim PS, et al. Pulmonary embolism response to fragmentation, embolectomy, and catheter thrombolysis (PERFECT): initial results from a prospec- tive multicenter registry. Chest. 2015;148:667–73. PMID: 25856269 Piazza G et al. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. JACC 2015; 8(10_ 1382 – 92. PMID: 26315743 Chatterjee S et al. Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage: A Meta-Analysis. JAMA 2014; 311 (23): 2414 – 2421. PMID: 24938564 Meyer G et al. Fibrinolysis for Patients with Intermediate-Risk Pulonary Embolism. NEJM 2014; 370(15): 1402 – 1411. PMID: 24716681 Konstantinides S et al. Heparin Plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary Embolism. NEJM 2002; 347 (15): 1143 – 1150. PMID: 12374874 Stein PD et al. Intracerebral Hemorrhage with Thrombolytic Therapy for Acute Pulmonary Embolism. Am J Med 2012; 125(1): 50 – 6. PMID: 22115025 Kline JA et al. Treatment of Submassive Pulmonary Embolism with Tenecteplase or Placebo: Cardiopulmonary Outcomes at 3 Months: Multicenter Double-Blind, Placebo-Controlled Randomized Trial. J Thromb Haemost 2014; 12(4): 459 – 68. PMID: 24484241 Sharifi M et al. Moderate Pulmonary Embolism Treated with Thrombolysis (from the “MOPETT” Trial). Am J Cardiol 2013; 111(2): 273 – 7. PMID: 23102885 Wang C et al. Efficacy and Safety of Low Dose Recombinant Tissue-Type Plasminogen Activator for the Treatment of acute Pulmonary Thromboembolism: A Randomized, Multicenter, Controlled Trial. CHEST 2010; 137(2): 654 – 62. PMID: 19741062 Zhang Z et al. Lower Dosage of Recombinant Tissue-Type Plasminogen Activator (rt-PA) in the Treatment of Acute Pulmonary Embolism: A Systematic Review and Meta-Analysis. Thrombosis Research 2014; 133(3): 357 – 63. PMID: 24412030

Post Peer Reviewed By: Anand Swaminathan (Twitter: @EMSwami)